Literature DB >> 4921093

The virulence of some strains of BCG for golden hamsters. Further studies.

K Bunch-Christensen, A Ladefoged, J Guld.   

Abstract

In principle, a strain of BCG used for the preparation of live vaccine should retain a moderate residual virulence. The inoculation of golden hamsters with large doses of BCG causes progressive, fatal disease but not all strains are equally active. In a previous paper, the present authors gave data from experiments with 9 BCG strains; in this report, 4 additional strains, three of which are in routine use in vaccine-production laboratories, are compared with one of the strains used in the previous experiments. The five strains differ widely in their ability to kill hamsters and were ranked in nearly the same order in two identically designed experiments. The differences in virulence found between strains derived relatively recently from a single mother strain were particularly noticeable. These differences were sometimes accompanied by striking changes in the growth characteristics of the strains with a lower virulence. The hypothesis that the lower virulence in such cases is a sign of genetic mutation is consistent with the general biological experience that virulence is often lost in vitro but that it practically never increases.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4921093      PMCID: PMC2427658     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  4 in total

1.  THE VIRULENCE OF VARIOUS STRAINS OF BCG DETERMINED ON THE GOLDEN HAMSTER.

Authors:  A JESPERSEN; M W BENTZON
Journal:  Acta Tuberc Pneumol Scand       Date:  1964

2.  [Comparison between BCG strains of different origins: observations concerning BCG strains of Brazilian origin (Moreau strain)].

Authors:  W KURYLOWICZ
Journal:  Acta Tuberc Scand       Date:  1957

3.  [Problems of BCG Vaccination in Brazil].

Authors:  A De Assis
Journal:  Presse Med       Date:  1956-03-07       Impact factor: 1.228

4.  The virulence of some strains of BCG for golden hamsters.

Authors:  K Bunch-Christensen; A Ladefoged; J Guld
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

  4 in total
  8 in total

1.  Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety.

Authors:  J B Milstien; J J Gibson
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

2.  Drug resistance in the Swedish/Norwegian BCG strain.

Authors:  I Hesselberg
Journal:  Bull World Health Organ       Date:  1972       Impact factor: 9.408

Review 3.  Present knowledge of immunization against tuberculosis.

Authors:  H G Dam; K Toman; K L Hitze; J Guld
Journal:  Bull World Health Organ       Date:  1976       Impact factor: 9.408

4.  Crucial requirement for standardization during the development of novel recombinant BCG vaccines: Does the corresponding substrain background matter?

Authors:  P R Z Antas
Journal:  Hum Vaccin Immunother       Date:  2016-07-25       Impact factor: 3.452

5.  The protective effect in bank voles of some strains of BCG.

Authors:  A Ladefoged; K Bunch-Christensen; J Guld
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

6.  A Modified Bacillus Calmette-Guérin (BCG) Vaccine with Reduced Activity of Antioxidants and Glutamine Synthetase Exhibits Enhanced Protection of Mice despite Diminished in Vivo Persistence.

Authors:  Carolyn M Shoen; Michelle S DeStefano; Cynthia C Hager; Kyi-Toe Tham; Miriam Braunstein; Alexandria D Allen; Hiriam O Gates; Michael H Cynamon; Douglas S Kernodle
Journal:  Vaccines (Basel)       Date:  2013-01-11

Review 7.  Evolution of M. bovis BCG Vaccine: Is Niacin Production Still a Valid Biomarker?

Authors:  Sarman Singh; Manoj Kumar; Pragati Singh
Journal:  Tuberc Res Treat       Date:  2015-01-28

8.  Reducing the activity and secretion of microbial antioxidants enhances the immunogenicity of BCG.

Authors:  Shanmugalakshmi Sadagopal; Miriam Braunstein; Cynthia C Hager; Jie Wei; Alexandria K Daniel; Markian R Bochan; Ian Crozier; Nathaniel E Smith; Hiriam O Gates; Louise Barnett; Luc Van Kaer; James O Price; Timothy S Blackwell; Spyros A Kalams; Douglas S Kernodle
Journal:  PLoS One       Date:  2009-05-13       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.